Written and maintained by CASRAI Editorial Board
Published
On this page
The journal of clinical and translational science domain connects laboratory discoveries to clinical care and population health. The primary publication anchoring this discipline is the Journal of Clinical and Translational Science (JCTS), published by Cambridge University Press for the Association for Clinical and Translational Science (ACTS) and the Clinical Research Forum. Established in 2016, JCTS serves as the international forum for translational researchers examining research processes, workforce education, and infrastructure across the translation spectrum.
For investigators preparing manuscripts, this guide outlines JCTS governance, editorial scope across translation phases, indexing metrics, article processing charges, and submission steps.
What it is
The Journal of Clinical and Translational Science (eISSN: 2059-8661; NLM ID: 101689953) is an international, peer-reviewed, Gold Open Access journal. Published online continuously by Cambridge University Press, the journal released its inaugural issue in February 2017. As the official journal of ACTS, JCTS provides an open forum covering the complete translational research continuum.
The journal clarifies the bridge between basic research vs. applied research. Rather than focusing solely on clinical drug trials, JCTS emphasizes translation science: operational bottlenecks, clinical trial design innovations, consortium metrics, and translational workforce development.
Disambiguating similar journal titles is critical when selecting a target venue:
- Journal of Clinical and Translational Science (JCTS): Published by Cambridge University Press for ACTS and the Clinical Research Forum (eISSN 2059-8661). Focuses on translational processes, methodology, and workforce training.
- Clinical and Translational Science (CTS): Published by Wiley for ASCPT. Focuses on clinical pharmacology and pharmacometrics.
- Journal of Clinical and Translational Research (JCTR): An independent journal covering preclinical and clinical biology.
Who runs it and what it covers
Governance and editorial leadership
JCTS is co-sponsored by ACTS and the Clinical Research Forum. ACTS was founded in 2009 to support the NIH Clinical and Translational Science Awards (CTSA) consortium, representing investigators across academic health centers, government bodies, and industry.
The journal is directed by Editor-in-Chief Christopher J. Lindsell, PhD, Professor of Biostatistics and Bioinformatics at Duke University School of Medicine, supported by an international editorial board covering biostatistics, informatics, ethics, and regulatory science.
Disciplinary scope and translation stages
JCTS accepts submissions spanning four translational stages:
- T1 Translation (Bench to Bedside): Proof-of-concept human trials, phase 1 clinical studies, and molecular pathology translation.
- T2 Translation (Bedside to Patients): Phase 2/3 randomized trials, diagnostic evaluations, and clinical guideline formulation.
- T3 Translation (Patients to Practice): Implementation science, health services delivery, and electronic health record integration.
- T4 Translation (Practice to Population Health): Public health policy impact, epidemiology, and community interventions.
The journal also solicits manuscripts on workforce training, diversity in trials, and team science management.
Indexing and journal metrics
Bibliometric performance can be tracked through standard resources for how to look up a journal’s impact factor:
- Clarivate Journal Citation Reports: 2025 Impact Factor of 2.7, ranking 106 out of 191 in Medicine, Research & Experimental (ESCI).
- Scopus & SJR: Indexed in Scopus with an SJR of ~0.97, placing JCTS in Quartile 1 (Q1) for Medicine (miscellaneous).
- PubMed Central (PMC): All articles are indexed in the NLM catalog (NLM ID: 101689953) and deposited in PMC.
- DOAJ: Fully indexed in the Directory of Open Access Journals.
Article processing charges and waiver policies
JCTS operates under a Gold Open Access model (CC BY licenses) supported by Article Processing Charges (APCs):
- Standard APC: $3,655 USD (£2,610 GBP) for non-member corresponding authors.
- ACTS Member Rate: $1,830 USD (£1,305 GBP), a 50% discount for active ACTS members.
- Institutional Agreements: Cambridge University Press Read & Publish agreements cover 100% of APCs for affiliated authors.
- Waivers: Full waivers available via the Cambridge Open Equity Initiative and Research4Life for eligible low- and middle-income nations. Acceptance is decided independently of ability to pay.
How to search or use it
Submitting an article to JCTS or searching its archives involves six structured steps on Cambridge Core and ScholarOne:
- Select Manuscript Category: Match your work to JCTS format bounds:
- Research Articles: Up to 5,000 words, structured abstract <= 250 words, max 50 references, <= 7 figures/tables.
- Brief Reports: Up to 2,000 words, unstructured abstract <= 100 words, max 20 references, <= 3 figures/tables.
- Special Communications & Reviews: Methodological or policy syntheses under agreed lengths.
- Comply with ICMJE and Trial Guidelines: Ensure human subject studies meet ethical standards. Follow mandatory clinical trial registration and reporting compliance rules prior to enrollment, listing the registry number in the abstract.
- Map Author Roles with CRediT: Cambridge Core requires individual contributions to be tagged using the Contributor Roles Taxonomy, following standard CRediT author statement conventions.
- Assign Corresponding Author: Clarify corresponding author responsibilities for licensing, waiver verification, and peer-review correspondence.
- Sign in to ScholarOne: Access the submission portal at
https://mc.manuscriptcentral.com/jctsusing your account or ORCID iD. - Upload Files and Nominate Reviewers: Upload manuscript files and provide names, affiliations, and emails of at least four (4) qualified external peer reviewers without conflicts of interest.
Strengths and limits
Strengths
- Focus on Translation Processes: Welcomes methodology and workforce studies that clinical disease journals often decline as out-of-scope.
- Gold Open Access: Unrestricted global access under CC BY licensing ensures immediate dissemination.
- CTSA Network Ties: Close alignment with ACTS and the Clinical Research Forum provides visibility across academic medical centers.
- Automatic PMC Archiving: Directly fulfills NIH and funder public access mandates.
Limits
- Open Access Fees: The $3,655 USD standard APC requires grant or institutional support if member discounts do not apply.
- Process Over Pure Mechanism: Studies detailing basic biology without a clear translational framework are outside the scope.
- Administrative Requirements: Mandatory nomination of four external reviewers and full CRediT tagging require advance preparation.
Alternatives
Researchers consider several related journals depending on whether their focus is translational methodology, clinical pharmacology, or molecular medicine:
| Journal Title | Publisher & Sponsoring Body | Primary Scope & Focus | Open Access Model | Clarivate Indexing Status |
|---|---|---|---|---|
| Journal of Clinical and Translational Science (JCTS) | Cambridge University Press / ACTS & CR Forum | Translational process, methodology, workforce education, and T1–T4 research. | Gold Open Access (CC BY) | Emerging Sources Citation Index (JIF: 2.7) |
| Clinical and Translational Science (CTS) | Wiley / ASCPT | Clinical pharmacology, pharmacometrics, drug action, and translational therapeutics. | Gold Open Access | Science Citation Index Expanded (JIF: 3.5) |
| Science Translational Medicine | AAAS | Mechanistic preclinical and translational medicine across human disease models. | Hybrid (Subscription & OA) | Science Citation Index Expanded (JIF: 15.8) |
| Journal of Clinical Investigation (JCI) | American Society for Clinical Investigation (ASCI) | Mechanistic disease models and clinical pathophysiology. | Hybrid / Open Access | Science Citation Index Expanded (JIF: 13.3) |
| Translational Research | Elsevier | Laboratory-to-clinic investigation, biomarkers, and precision medicine. | Hybrid | Science Citation Index Expanded (JIF: 6.8) |
FAQ
What is the difference between JCTS and Wiley’s CTS?
Journal of Clinical and Translational Science (JCTS) is published by Cambridge University Press for ACTS and emphasizes translational processes, study design, and workforce education. In contrast, Clinical and Translational Science (CTS) is published by Wiley for ASCPT and focuses on clinical pharmacology and pharmacometrics.
Is the Journal of Clinical and Translational Science indexed in PubMed?
Yes. JCTS is cataloged under NLM ID 101689953, and all articles are deposited into PubMed Central (PMC), ensuring full PubMed indexing.
How much is the article processing charge for JCTS?
The standard APC is $3,655 USD (£2,610 GBP). Active ACTS corresponding members receive a 50% discount ($1,830 USD / £1,305 GBP). Waivers are available via institutional Read & Publish agreements and the Cambridge Open Equity Initiative.
What submission portal does JCTS use?
JCTS processes submissions through ScholarOne Manuscripts at https://mc.manuscriptcentral.com/jcts.
Does JCTS require CRediT taxonomy author statements?
Yes. Cambridge University Press and JCTS require author contributions to be specified using the Contributor Roles Taxonomy (CRediT).
Sources
- Cambridge Core: Journal of Clinical and Translational Science Homepage — Scope, editorial board, and Clarivate metrics (accessed 2026-11-11).
- Cambridge Core: Instructions for Contributors — Author guidelines, word counts, CRediT policies, and reviewer rules (accessed 2026-11-11).
- Association for Clinical and Translational Science (ACTS) — Governance, CTSA support, and member benefits (accessed 2026-11-11).
- National Library of Medicine Catalog (NLM ID: 101689953) — Serial publication details, eISSN 2059-8661, and PMC record (accessed 2026-11-11).







